Protagonist Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Protagonist Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Protagonist Therapeutics: 8 sponsored US clinical trials, none currently recruiting.

Protagonist Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Polycythemia Vera, with 2 trials.

Upper-quartile sponsor footprint

Protagonist Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

NCT06033586
ACTIVE NOT RECRUITING Phase 3

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

NCT05210790
COMPLETED Phase 2

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

NCT04504383
COMPLETED Phase 2

PTG-300 in Subjects With Hereditary Hemochromatosis

NCT04202965
COMPLETED Phase 2

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

NCT04057040
COMPLETED Phase 2

Safety Study for Beta Thalassemia Subjects on PTG-300

NCT04054921
COMPLETED Phase 2

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

NCT03802201
TERMINATED Phase 2

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

NCT02895100

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 2

Therapeutic Areas

Polycythemia Vera 2

How the Protagonist Therapeutics early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Polycythemia Vera (2 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Protagonist Therapeutics: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Protagonist Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Protagonist TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Protagonist Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Protagonist Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Protagonist Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Protagonist Therapeutics or any single study.

  • None of Protagonist Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Polycythemia Vera is the condition Protagonist Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Polycythemia Vera trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Protagonist Therapeutics pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.